Clinical trials
SLE (Systemic Lupus) clinical trials
Below are recruiting sle (systemic lupus) clinical trials, each written for real people, not researchers. We’re tracking 222 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07053800RecruitingPhase 2
Obe-cel for severe lupus with kidney inflammation
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
New York, New YorkAges 12–65 - NCT05440422RecruitingPhase 2
Anifrolumab for heart and blood vessel health in lupus
This trial tests whether a drug called anifrolumab can improve early signs of heart and blood vessel damage in people with lupus. It may help prevent future heart problems and strokes.
Bethesda, MarylandAges 18–80 - NCT05352919Enrolling by invitationPhase 3
Long-term study of litifilimab for lupus symptom control
This study follows people with systemic lupus erythematosus (SLE) who already took part in an earlier, 1-year placebo-controlled trial. It looks at the long-term safety of litifilimab and whether it helps improve lupus symptoms over time.
Phoenix, ArizonaAges 18 years+ - NCT07598396RecruitingPhase 2
Mosunetuzumab for systemic lupus erythematosus treatment
This study tests a new drug called mosunetuzumab in people with systemic lupus erythematosus (SLE), a disease where the immune system attacks the body's own tissues. The drug is designed to help control the immune response and reduce lupus symptoms, including kidney involvement if present.
Salvador, Estado de BahiaAges 18 years+ - NCT07409181RecruitingPhase 2
Testing an experimental pill for active lupus (SLE)
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
Beverly Hills, CaliforniaAges 18–74 - NCT07447986RecruitingPhase 2
Testing a New Injection for Lupus (SLE)
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
Beijing, Beijing MunicipalityAges 18–70 - NCT07570862RecruitingPhase 2
CAR T-Cell Therapy for Hard-to-Treat Lupus Kidney Disease
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
Beverly Hills, CaliforniaAges 12–70 - NCT07332481RecruitingPhase 3
Testing enpatoran for lupus affecting the skin
This trial tests if a drug called enpatoran can help people with lupus that causes skin rashes, like discoid lupus or subacute cutaneous lupus. It may be for those with or without systemic lupus.
Los Angeles, CaliforniaAges 18–75 - NCT07760480RecruitingPhase 4
Intensified treatment for lupus nephritis
This study tests whether adding a drug called voclosporin to the usual treatment for lupus nephritis (a kidney disease caused by lupus) can better reduce kidney inflammation. It also looks at the role of immune cells in this process.
AmsterdamAges 16–70 - NCT06977724RecruitingPhase 1
Testing a new drug for lupus, sjogren's, and rheumatoid arthritis
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
Avon Park, FloridaAges 18–75 - NCT07483346RecruitingPhase 1
Testing IASO-782 for systemic lupus erythematosus
This trial tests a new medicine called IASO-782 for people with systemic lupus erythematosus (SLE). It aims to see if the drug can help control lupus symptoms when added to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07564596RecruitingPhase 1/Phase 2
A Study of Budoprutug for Systemic Lupus Erythematosus
This trial tests budoprutug, an experimental drug, to see if it helps people with systemic lupus erythematosus (SLE) whose disease is not well controlled by current treatments. The drug targets immune cells that may be driving the disease.
Mianyang, SichuanAges 18–65 - NCT07311200RecruitingPhase 2
Study of D-2570 for active lupus
This trial tests a new oral medication called D-2570 for people with active systemic lupus erythematosus (SLE). It aims to see if the drug can help control lupus symptoms while you continue your current stable treatments.
Linfen, JiangxiAges 18–70 - NCT07713940Recruiting
Anti-inflammatory diet study for lupus patients
This study tests whether an anti-inflammatory diet can help people with lupus who are on certain medications. It focuses on reducing pain and improving quality of life over 12 weeks.
La Jolla, CaliforniaAges 18 years+ - NCT07260877RecruitingPhase 2
Testing VENT-03 for active skin lupus with or without systemic lupus
This study tests an experimental medicine called VENT-03 to see if it can improve skin lupus symptoms in adults. It compares VENT-03 against a placebo (a pill with no active drug) and includes a longer-term option where everyone can get the real drug. The goal is to find a new treatment for people whose lupus affects their skin.
Beverly Hills, CaliforniaAges 18–80 - NCT07720310Enrolling by invitation
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new immune cell therapy (CAR-T) for people with lupus that hasn't gotten better with standard treatments. The goal is to see if these modified cells can calm the overactive immune system and improve symptoms.
Lyasny, Minsk OblastAges 18–70 - NCT07175285Recruiting
Study for lupus patients not helped by steroids and 2 immunosuppressants
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
Mesa, ArizonaAges 16 years+ - NCT07237659RecruitingPhase 1
Testing safety of NTR-1011 in lupus and rheumatoid arthritis
This trial is testing a new medicine called NTR-1011 to see if it is safe and tolerable for people with lupus or rheumatoid arthritis. If you have active lupus or RA and are on a stable treatment plan, you may be able to join.
Apple Valley, CaliforniaAges 18–75 - NCT07276958RecruitingPhase 1
Study of LY4298445 for Lupus and Rheumatoid Arthritis
This trial tests a new drug called LY4298445 in healthy people and those with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how the body processes it.
BrisbaneAges 18–55 - NCT06917742RecruitingPhase 1
Study of CPTX2309 for rheumatoid arthritis and lupus
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
Herston, QueenslandAges 18–65 - NCT04604990Recruiting
National lupus patient study for adults in Saudi Arabia
This study follows adults with systemic lupus erythematosus (lupus) to better understand the condition over time. If you meet common lupus diagnosis standards, you may be able to join—there’s no limit on when you were diagnosed.
Riyadh, Central ProvinceAges 19 years+ - NCT04702256RecruitingPhase 3
Treating lupus kidney inflammation with or without extra steroid tablets
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
ParisAges 14 years+ - NCT05688696RecruitingPhase 2
Testing a drug called orelabrutinib for lupus symptoms in adults
This Phase 2 trial studies whether orelabrutinib can improve systemic lupus erythematosus (SLE) and check its safety. It may help people with active lupus who are already on stable lupus medicines.
Bengbu, AnhuiAges 18–75 - NCT05714930Recruiting
Treating lupus symptoms to a clear goal
This study looks at a “treat-to-target” approach for people with systemic lupus erythematosus (SLE) to help control symptoms to a specific goal. It may help guide medication changes when lupus is not fully calm yet.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+
Hear when a new SLE (Systemic Lupus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sle (systemic lupus)?
- Yes. Clin2 currently lists 222 recruiting sle (systemic lupus) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sle (systemic lupus) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sle (systemic lupus) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.